The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

Jefferies warns of high attrition in TCS following the layoff debacle, while Nasscom posts an impersonal response; Tata Consultancy Services shares continue to tank, falling 25 per cent in six months ...

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...

Huntington Ingalls Industries ( NYSE: HII) shares jumped more than 5% in premarket trading Thursday after the U.S. defense ...

I've been writing about the LG C3 OLED TV since its release in 2023, and it has consistently been a best-seller, thanks to ...

This leader in cloud observability is swiftly moving into the artificial intelligence space, and it's having major success.